Both Hemophilia Health Care Providers and Hemophilia A Carriers Report That Carriers Have Excessive Bleeding

Abstract

Introduction Hemophilia A, the result of reduced factor VIII (FVIII) activity, is an X-linked recessive bleeding disorder. Previous reports of Hemophilia A carriers suggest an increased bleeding tendency. Our objective was to determine the attitudes and understanding of the Hemophilia A carrier bleeding phenotype, and opinions regarding timing of carrier testing from the perspective of both medical providers and affected patients. Data from this survey was used as preliminary data for an ongoing prospective study. Material and Methods An electronic survey was distributed to physicians and nurses employed at Hemophilia Treatment Centers (HTC), and Hemophilia A carriers who were members of Hemophilia Federation of America. Questions focused on the clinical understanding of bleeding symptoms and management of Hemophilia A carriers, and the timing and intensity of carrier testing. Results Our survey indicates that 51% (36/51) of providers compared to 78% (36/46) of carriers believe that Hemophilia A carriers with normal FVIII activity have an increased bleeding tendency (p<0.001); 72% (33/36) of Hemophilia A carriers report a high frequency of bleeding symptoms. Regarding carrier testing, 72% (50/69) of medical providers recommend testing after 14 years of age, conversely 65% (29/45) of Hemophilia A carriers prefer testing to be done prior to this age (p<0.001). Discussion Hemophilia A carriers self-report a higher frequency of bleeding than previously acknowledged, and have a preference for earlier testing to confirm carrier status.

A diagnostic approach to mild bleeding disorders

“…Both mild HA and mild HB are defined as FVIII:C or FIX:C > 5–40% of normal (see Table ) . Determination of FVIII:C or FIX:C should be performed in hemophilia carriers, but carriers may have an increased bleeding tendency even when factor levels are normal . Mutation analysis of the F8 or F9 genes is widely performed for genetic counselling and can confirm carriership.…”

Barriers and challenges faced by women with congenital bleeding disorders in Europe: Results of a patient survey conducted by the European Haemophilia Consortium

“…The historical perspective of haemophilia as the archetypal bleeding disorder, affecting only males, casts a long shadow over the evaluation of WBD. Congenital bleeding disorders (CBD) encompass a broad array of platelet function and coagulation factor defects, many of which affect both males and females equally, yet women still struggle to gain recognition from physicians that they have pathological bleeding . Compared to their male counterparts, WBD not only experience general bleeding symptoms, but also undergo a monthly haemostatic challenge of menstruation in addition to the increased risk of excessive bleeding associated with childbirth.…”

The national blueprint for pregnancy/birth longitudinal cohorts to study factor VIII immunogenicity: NHLBI State of the Science (SOS) Workshop on factor VIII inhibitors

“…Prenatal genotype can inform risk for inhibitors . Carriers overall have lower coagulation factor levels and bleed more than other women, and therefore should be patients. At HTCs, 7%‐12% of haemophilia patients are female .…”